Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 701 - 750 out of 5,290

Document Document Title
WO/2005/042489A1
Disclosed are N-substituted benzenesulfonamides for use intreating in treating or preventing cognitive disorders, such as Alzheimer´s Disease. Formula (I) In formula (I), R1, R2, R3, R4, R3’, R10 and R11 are described herein. The inve...  
WO/2005/042491A1
The present invention relates to substituted-2,3,4,5-tetrahydro-3-benzazepine derivatives that are modulators of the 5HT2C receptor. Accordingly, compounds of the present invention are useful for the prophylaxis or treatment of 5HT2C rec...  
WO/2005/042490A1
The present invention relates to substituted-2,3,4,5-tetrahydro-3-benzazepine derivatives that are modulators of the 5HT2C receptor. Accordingly, compounds of the present invention are useful for the prophylaxis treatment of 5HT2C recept...  
WO/2005/042697A2
Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.  
WO/2005/040108A1
This invention is related to novel prolinamide derivatives and analogues of general formula (I) wherein Q is C3-C8 alkyl, or C1-C8 alkyl substituted by phenoxy or saturated or unsaturated 5 to 7 membered ring optionally containing one or...  
WO/2005/039591A1
The present invention relates to novel benzazepine derivatives of the following formula: (I) wherein R1, R2, R3, R4 and R5, X, X’, Y and Y’ are as defined in the description and claims, processes for their preparation, pharmaceutical...  
WO/2005/040126A1
The present invention relates to compounds of the general formula (I) Wherein R1 is -(CHR’)q-aryl or -(CHR')q-heteroaryl, which are unsubstituted or mono, di- or tri-substituted by lower alkyl, lower alkoxy, CF3 or halogen, or is lower...  
WO2004093817A3
Compounds that interact with the CXCR4 receptor are described. The compounds are useful in treating for Example, HIV infection and inflammatory conditions such as rheumatoid arthritis, as well as asthma or cancer, and are useful in metho...  
WO/2005/037269A1
A compound represented by the following formula (1), a prodrug thereof, or a pharmaceutically acceptable salt of either. They are effective in enhancing LDL receptor manifestation and are useful as a therapeutic agent for hyperlipemia, a...  
WO/2005/037796A1
Compounds of formula I wherein n, m, p, q, Y, R1 R2, R3, R4, R5, and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating artherosclerosis and its sequelae.  
WO2005007630A3
This invention is directed to compounds of the formula (I): and their pharmaceutically acceptable salts, wherein R<1>, R<2>, R<3> and Z are as defined herein; intermediates for the synthesis of such compounds, pharmaceutical compositions...  
WO/2005/037785A2
The invention relates to compounds having general formula (I), wherein: n represents the number 1 or 3; R1 represents either H or a cycloalkyl, cycloalkylalkyl, phenylalkyl, alkenyl, alkynyl group; X represents either H or one or more su...  
WO/2005/037795A2
The invention is directed to nonpeptide substituted benzazepines of Formula (I), which are useful as vasopressin receptor antagonists for treating conditions associated with vasopressin receptor activity such as those involving increased...  
WO/2005/035504A2
The present invention provides compounds of formula (I), which, are novel antagonists for D1/D5 receptors as well as methods for preparing such compounds. In another embodiment, the invention provides pharmaceutical compositions comprisi...  
WO/2005/030730A1
An industrially advantageous production process which is an improved process for the production of an optically active &agr -amino-&epsiv -caprolactam (ACL). By the process, a desired optically active isomer having a high optical purity ...  
WO/2005/030794A2
The present invention provides compounds having formula (I): and additionally provides methods for the synthesis thereof and methods for the use thereof in the treatment of cancer, wherein R1-R7, X1, X2, R, Q, and n are as defined herein.  
WO2004080932A3
A method for recovering hexamethylene diamine (HMD) from a mixture (18) comprising HMD, 6-aminocapronitrile (ACN) tetrahydroazepine (THA), and ADN comprising: (a) introducing the mixture into a distillation column (20) capable of separat...  
WO/2005/023772A1
The invention relates to malonamide derivatives of formula (I), wherein: R1 is one of the following groups (Formulae a), b), c), d)); R2 is lower alkyl, lower alkinyl, -(CH2)n-O-lower alkyl, -(CH2)n-S-lower alkyl, -(CH2)n-CN, -(CR'R')n-C...  
WO2005009972A3
The present invention relates to an improved process for preparation of highly pure benazepril of Formula I, wherein R is hydrogen or pharmacologically acceptable salt thereof by completely eliminating the impurity of 7-bromo analogue of...  
WO2004096795A3
The invention is directed to compounds of formulae (I), (II) and (III), wherein A, R1, R2, R3, R4, X, Y and W are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that...  
WO/2005/021487A1
This invention relates to a novel class of compounds, represented by the formula (I) below, wherein the meanings of R1, R2, R3 and R4 are indicated therein, which are cysteine protease inhibitors, including but not limited to, inhibitors...  
WO/2005/019180A1
The present invention provides a 7-chloro-6-(2,2,2-trifluoroethylamino)-2,3,4,5-tetrahydro-1H -benzo[d]azepine of formula (I): or a pharmaceutically acceptable salt thereof, and its use as a selective 5-HT2c agonist for the treatment of ...  
WO/2005/019179A2
The present invention provides processes and intermediates for the preparation of 3-benzazepines and salts thereof which can be useful as serotonin (5-HT) receptor agonists for the treatment of , for example, central nervous system disor...  
WO/2005/016891A1
The invention provides compounds of formula (I): wherein A and B represent the groups -(CH2)m- and -(CH2)n- respectively; R1 represents hydrogen or C1-6alkyl; R2 represents hydrogen, halogen, hydroxy, cyano, nitro, hydroxyC1-6alkyl, trif...  
WO/2005/014578A1
The invention provides compounds of formula (I): wherein A and B represent the groups -(CH 2) m- and -(CH 2) n- respectively; R1 represents hydrogen or C1-6alkyl; R2 represents hydrogen, halogen, hydroxy, cyano, nitro, hydroxyC 1-6 alkyl...  
WO/2005/014574A1
This invention relates to certain substituted lactam compounds of the formula (I), particularly caprolactam compounds, which are useful for the treatment of cancer.  
WO2004002491A8
The present invention relates to novel cathepsin S inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.  
WO/2005/012266A1
The present invention relates to new D3 and D2 dopamine receptor subtype preferring ligands of formula (I): wherein R1 and R2 represent independently a substituent selected from hydrogen, alkyl, aryl, cycloalkyl, aroyl, or R1 and R2 may ...  
WO2004110983A3
Compounds of general structure (I), wherein the central benzene ring may be substituted in the meta- or para-­position; -A is an optionally substituted hydroxyl, alkoxyl, hydroxylamine, alkoxylamine or amine radical; -W is an N- ­and C...  
WO/2005/009972A2
The present invention relates to an improved process for preparation of highly pure benazepril of Formula I, wherein R is hydrogen or pharmacologically acceptable salt thereof by completely eliminating the impurity of 7-bromo analogue of...  
WO/2005/007630A2
This invention is directed to compounds of the formula (I): and their pharmaceutically acceptable salts, wherein R1, R2, R3 and Z are as defined herein; intermediates for the synthesis of such compounds, pharmaceutical compositions conta...  
WO/2005/005392A1
Compounds of the formula (I), and pharmaceutically acceptable salts thereof, are found to be antagonists of SNS sodium channels. They are therefore useful as analgesic and neuroprotective agents wherein: X is -N- or -CH-; n is from 0 to 3.  
WO/2005/003096A1
The present invention relates to certain 1-substituted-2,3,4,5-tetrahydro-3-benzazepine derivatives of Formula (I), that are modulators of the 5HT2C receptor. Accordingly, compounds of the present invention are useful for the prophylaxis...  
WO/2005/000819A1
Novel spirobenzoazepine compounds, novel processes for the preparation of nonpeptide substituted spirobenzoazepine dervatives, and novel processes for the preparation of intermediates in the preparation of such derivatives. Novel interme...  
WO/2004/113288A1
Method for making caprolactam from 6-aminocapronitrile that contains greater than 500 ppm tetrahydroazepine and its derivatives (THA) in which ammonia and water are removed from crude caprolactam in a single separation step and then THA ...  
WO/2004/113297A2
This invention relates to novel aza-dng dedvatives useful as monoamine neurotransmifter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions...  
WO/2004/110986A1
A compound which functions to inhibit capsaicin receptor VR1 activation and is useful as a therapeutic agent for, e.g., various pains including inflammatory pain and neurogenic pain, migraine, cluster headache, and bladder diseases inclu...  
WO/2004/110983A2
Compounds of general structure (I), wherein the central benzene ring may be substituted in the meta- or para-­position; -A is an optionally substituted hydroxyl, alkoxyl, hydroxylamine, alkoxylamine or amine radical; -W is an N- ­and C...  
WO/2004/099153A1
A high-yielding method for racemisation of (S)-(+)- and (R)-(-)-10, 11- dihydro-l0-­hydroxy-5H-dibenz/b,f/azepine-5-carboxamide and a useful intermediate, 10-chloro-10, 11 dihydro-5H-dibenz/b,f/azepine-5-carboxamide (VII) are disclosed....  
WO/2004/096795A2
The invention is directed to compounds of formulae (I), (II) and (III), wherein A, R1, R2, R3, R4, X, Y and W are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that...  
WO2004067675A3
A blue electroluminescent material based on a binaphtyl compound of the general formula (I). Particular embodiments having the general formula have good solubilities in common organic solvents, resist crystallization and can be sublimed ...  
WO/2004/096775A1
A novel 4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivative represented by the following formula (I) or a pharmaceutically acceptable salt of the derivative. They are useful as a therapeutic or preventive agent for night pollakis...  
WO/2004/094387A1
Disclosed herein is an antioxidant that is an alkylated iminodibenzyl of the general formula: (I) wherein: R1, R2, R3, and R4 are independently selected from the group consisting of hydrogen, alkyl moieties, and alkenyl moieties; and R5,...  
WO2003103662A3
The Invention provides use of an antibody against platelet glycoprotein VI (GPVI) for the preparation of a medicament for the prevention of intraarterial thrombosis in a Patient characterized by (i) having suffered from an acute coronary...  
WO/2004/093796A2
Lactam derivatives of the general formula (I), are disclosed. Pharmaceutical compositions containing the compounds and methods for their use are also disclosed.  
WO2004042351A3
The present invention is directed to compounds of the formula (I): (wherein R¿1<, R¿2?, R¿3?, R¿4?, R¿5?, R¿6?, W, X, Z, m and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, thes...  
WO/2004/093817A2
Compounds that interact with the CXCR4 receptor are described. The compounds are useful in treating for Example, HIV infection and inflammatory conditions such as rheumatoid arthritis, as well as asthma or cancer, and are useful in metho...  
WO/2004/089890A2
Disclosed is a new process and intermediates for preparing benzazepines of Formula wherein R1 and R2 are as defined herein.  
WO2003097163A3
Therapeutic methods for the prevention and treatment of respiratory diseases or conditions are described, the methods including administering to a subject in need thereof a respiratory disease or condition effective amount of a selective...  
WO1995018619A9
Certain compounds within formula (I) are inhibitors of platelet aggregation wherein A<1> is NH or CH<2>; R is H, C1-6alkyl, benzyl or a carboxy protecting group; R<3> is C1-6alkyl, Ar- C0-6alkyl, C1-6cycloalkyl C0-6alkyl, or Het C0-6alky...  

Matches 701 - 750 out of 5,290